STOCK TITAN

EFFECTOR THERAPUTCS INC - EFTR STOCK NEWS

Welcome to our dedicated page for EFFECTOR THERAPUTCS news (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on EFFECTOR THERAPUTCS stock.

eFFECTOR Therapeutics, Inc., headquartered in San Diego, is a cutting-edge biotechnology company that focuses on developing a novel class of oncology drugs known as selective translation regulator inhibitors (STRIs). The company's mission is to advance cancer treatment by targeting key molecular mechanisms that drive the disease.

eFFECTOR's flagship product, zotatifin, is currently under Phase 1/2 clinical trials for ER+/HER2- metastatic breast cancer. Recently, zotatifin received Fast Track designation from the U.S. FDA in combination with fulvestrant and abemaciclib, underscoring its potential in treating advanced or metastatic breast cancer. In these trials, zotatifin showed promising results with a 26% partial response rate in heavily pretreated patients.

Another key product in eFFECTOR's pipeline is tomivosertib, an MNK inhibitor being evaluated in a Phase 2b trial for metastatic non-small cell lung cancer (NSCLC). The company's research extends to other biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.

eFFECTOR is also collaborating globally with Pfizer to develop inhibitors targeting eIF4E, further enhancing its research capabilities and clinical development. This partnership aims to streamline the translation of groundbreaking findings into viable treatments for cancer patients.

Financially, eFFECTOR continues to strengthen its position through strategic offerings, raising approximately $15 million in recent direct offerings. This capital helps advance their research projects and maintain a robust developmental pipeline.

Additionally, eFFECTOR announced a reverse stock split aimed at regaining compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024. This move is intended to better position the company within the stock market, ensuring long-term growth and stability.

Stay updated with eFFECTOR's latest developments as they continue to innovate in the field of oncology, pushing the boundaries of cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.76%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.76%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
conferences
-
Rhea-AI Summary

eFFECTOR Therapeutics has announced that a poster presentation highlighting results from a Phase 2 expansion study of zotatifin in ER+ Metastatic Breast Cancer will be presented at the ASCO 2023 Annual Meeting. The results will be discussed in a conference call following the presentation on June 4, 2023. Abstracts will be available on May 25, 2023. eFFECTOR, a leader in selective translation regulator inhibitors (STRIs), focuses on developing innovative oncology drugs targeting critical cancer pathways. The lead candidate, tomivosertib, is undergoing a Phase 2b trial in combination with pembrolizumab for metastatic non-small cell lung cancer. Zotatifin is also under evaluation in various biomarker-positive solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.49%
Tags
conferences clinical trial
-
Rhea-AI Summary

eFFECTOR Therapeutics has announced a clinical collaboration to evaluate zotatifin, an eIF4A inhibitor, in patients with ER+ breast cancer. This trial, led by Dr. Jennifer Caswell-Jin at Stanford Medicine, will focus on specific genomic subgroups, including high-risk patients. The goal is to assess zotatifin's impact on tumor growth compared to standard care, particularly in patients at risk of relapse. The trial's primary objective is to measure changes in tumor proliferation after treatment. This collaboration aims to leverage genomic predictive technologies to improve treatment outcomes for breast cancer patients. Through this study, eFFECTOR hopes to enhance the precision of targeted therapies and address the high rates of relapse observed in ER+ breast cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.28%
Tags
Rhea-AI Summary

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced its participation in two upcoming investor conferences, emphasizing its focus on cancer treatment through selective translation regulator inhibitors (STRIs). The events include a Fireside Chat at Cantor's Future of Oncology Virtual Symposium on April 3, 2023, at 11 AM ET and another at Stifel's Targeted Oncology Days on April 25, 2023, at 2 PM ET. A live webcast of the Stifel event will be accessible on the company's Investors page, with replays available for 90 days. eFFECTOR is advancing innovative therapies targeting critical protein synthesis pathways to combat tumor growth, with lead candidate tomivosertib currently in Phase 2b trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences

FAQ

What is the current stock price of EFFECTOR THERAPUTCS (EFTR)?

The current stock price of EFFECTOR THERAPUTCS (EFTR) is $0.03245 as of October 15, 2024.

What is the market cap of EFFECTOR THERAPUTCS (EFTR)?

The market cap of EFFECTOR THERAPUTCS (EFTR) is approximately 611.6K.

What is eFFECTOR Therapeutics' primary focus?

eFFECTOR Therapeutics focuses on developing selective translation regulator inhibitors (STRIs) for cancer treatment.

What recent achievement did eFFECTOR announce?

The FDA granted Fast Track designation for zotatifin in combination with fulvestrant and abemaciclib for treating ER+/HER2- metastatic breast cancer.

What products are in eFFECTOR's pipeline?

Key products include zotatifin and tomivosertib, targeting various solid tumors and metastatic cancers.

How is eFFECTOR collaborating with other companies?

eFFECTOR has a global collaboration with Pfizer to develop inhibitors targeting eIF4E.

What are the financial highlights of eFFECTOR?

eFFECTOR raised approximately $15 million through a recent direct offering to support its research and development efforts.

What is the significance of the recent reverse stock split?

The reverse stock split aims to regain compliance with Nasdaq's minimum bid price requirements, effective January 12, 2024.

What types of cancer are eFFECTOR's products targeting?

Their products target various solid tumors, including ER+ breast cancer, KRAS-mutant NSCLC, and metastatic non-small cell lung cancer.

What is the potential benefit of zotatifin's Fast Track designation?

It facilitates development and expedited review, potentially bringing the treatment to market faster.

How is eFFECTOR funded for its developments?

Through strategic offerings and collaborations, eFFECTOR continues to secure the financial resources needed for its research.

What are the recent clinical trial results for zotatifin?

In recent trials, zotatifin showed a 26% partial response rate in heavily pretreated patients with ER+/HER2- metastatic breast cancer.

EFFECTOR THERAPUTCS INC

Nasdaq:EFTR

EFTR Rankings

EFTR Stock Data

611.57k
4.70M
2.91%
21.73%
1.95%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOLANA BEACH